PPD, Schrödinger, Beam set terms for IPO; FDA ex­pands use of Mer­ck­'s Di­fi­cid

→ With slow­er rates of pa­tient en­roll­ment than ex­pect­ed for their Phase III tri­al of its PARP in­hibitor pami­parib vs place­bo — as a ther­a­py in pa­tients with in­op­er­a­ble lo­cal­ly ad­vanced or metasta­t­ic gas­tric can­cer who have re­spond­ed to plat­inum-based first line chemother­a­py — BeiGene is con­vert­ing the tri­al to a Phase II. Pa­tient en­roll­ment be­gan in Ju­ly 2018 and the com­pa­ny has thus far reg­is­tered ap­prox­i­mate­ly 120 pa­tients glob­al­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER